ストックスクリーナーアプリを入手
1.47
0.68%
0.01
アフターアワーズ：
1.47
前日終値:
$1.46
開ける：
$1.46
24時間の取引高:
46,762
Relative Volume:
0.42
時価総額：
$109.54M
収益：
-
当期純損益:
$-19.57M
株価収益率:
-0.4696
EPS:
-3.13
ネットキャッシュフロー:
$-17.24M
1週間 パフォーマンス:
-4.55%
1か月 パフォーマンス:
-9.26%
6か月 パフォーマンス:
-34.96%
1年 パフォーマンス:
-41.90%
1日の値動き範囲:
$1.43
$1.49
1週間の範囲:
$1.43
$1.595
52週間の値動き範囲:
$1.415
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
名前
Inhibikase Therapeutics Inc
セクター
電話
(302) 295-3800
住所
1000 N. WEST STREET, SUITE 1200, WILMINGTON
IKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.47 | 108.79M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc (IKT) 最新ニュース
Can Inhibikase Therapeutics Inc. stock reach $100 price targetJuly 2025 Selloffs & Intraday High Probability Setup Alerts - newser.com
Tools to monitor Inhibikase Therapeutics Inc. recovery probabilityJuly 2025 Action & Weekly High Potential Alerts - newser.com
Is Inhibikase Therapeutics Inc. (IQT0) stock a defensive play amid uncertaintyWall Street Watch & Long-Term Capital Growth Strategies - newser.com
What institutional flow reveals about Inhibikase Therapeutics Inc.Insider Buying & Weekly Stock Performance Updates - newser.com
Will Inhibikase Therapeutics Inc. stock attract ESG investorsTrade Volume Report & Community Consensus Stock Picks - newser.com
Can Inhibikase Therapeutics Inc. recover in the next quarterWeekly Loss Report & Community Verified Swing Trade Signals - newser.com
How Inhibikase Therapeutics Inc. stock compares to growth peersJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
Why Inhibikase Therapeutics Inc. stock appeals to analystsEarnings Growth Report & Long-Term Growth Portfolio Plans - newser.com
Is Inhibikase Therapeutics Inc. reversing from oversold territoryBreakout Watch & Free Growth Oriented Trading Recommendations - newser.com
Will Inhibikase Therapeutics Inc. stock beat EPS estimatesJuly 2025 Breakouts & Daily Volume Surge Signals - newser.com
Will Inhibikase Therapeutics Inc. price bounce be sustainableJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Will Inhibikase Therapeutics Inc. (IQT0) stock top growth indexes2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock fits value portfolios2025 Price Action Summary & Real-Time Price Movement Reports - newser.com
What makes Inhibikase Therapeutics Inc. stock attractive to growth fundsTrade Entry Report & Weekly Stock Breakout Alerts - newser.com
How to build a dashboard for Inhibikase Therapeutics Inc. stockQuarterly Investment Review & Capital Protection Trade Alerts - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock is a strong analyst pickTrade Risk Assessment & AI Based Buy/Sell Signal Reports - newser.com
Will Inhibikase Therapeutics Inc. (IQT0) stock profit from AI boomEarnings Overview Report & Long-Term Growth Portfolio Plans - newser.com
Why Inhibikase Therapeutics Inc. stock is a must watch in 2025July 2025 Intraday Action & Low Drawdown Investment Strategies - newser.com
Analyzing Inhibikase Therapeutics Inc. with risk reward ratio chartsWeekly Risk Report & Reliable Volume Spike Alerts - newser.com
Vor Biopharma (NASDAQ:VOR) & Inhibikase Therapeutics (NASDAQ:IKT) Critical Review - Defense World
Key resistance and support levels for Inhibikase Therapeutics Inc.July 2025 Institutional & Risk Controlled Daily Plans - newser.com
Inhibikase Therapeutics Inc (IKT) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):